Literature DB >> 25637942

Northern Territory perspectives on heart failure with comorbidities – understanding trial validity and exploring collaborative opportunities to broaden the evidence base.

P Iyngkaran1, W Majoni2, A Cass3, Prashanthan Sanders4, C Ronco5, S Brady6, N Kangaharan7, M Ilton8, D L Hare9, M C Thomas10.   

Abstract

Congestive Heart Failure (CHF) is an ambulatory care sensitive condition, associated with significant morbidity and mortality, rarely with cure. Outpatient based pharmacological management represents the main and most important aspect of care, and is usually lifelong. This narrative styled opinion review looks at the pharmacological agents recommended in the guidelines in context of the Northern Territory (NT) of Australia. We explore the concept of validity, a term used to describe the basis of standardising a particular trial or study and the population to which it is applicable. We aim to highlight the problems of the current guidelines based approach. We also present alternatives that could utilise the core principles from major trials, while incorporating regional considerations, which could benefit clients living in the NT and remote Australia.
Copyright © 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Guidelines; Heart Failure; Indigenous Australians; Remote; Rural; Therapeutics

Mesh:

Substances:

Year:  2014        PMID: 25637942     DOI: 10.1016/j.hlc.2014.12.007

Source DB:  PubMed          Journal:  Heart Lung Circ        ISSN: 1443-9506            Impact factor:   2.975


  8 in total

1.  Heart Failure Paradigms in the Developed World - A Reflection - Part 1

Authors:  Pupalan Iyngkaran; David L Hare
Journal:  Curr Cardiol Rev       Date:  2021

2.  Trends in prevalence of comorbidities in heart failure clinical trials.

Authors:  Muhammad Shahzeb Khan; Ayman Samman Tahhan; Muthiah Vaduganathan; Stephen J Greene; Alaaeddin Alrohaibani; Stefan D Anker; Orly Vardeny; Gregg C Fonarow; Javed Butler
Journal:  Eur J Heart Fail       Date:  2020-04-15       Impact factor: 15.534

Review 3.  Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice.

Authors:  Pupalan Iyngkaran; Merlin Thomas; John D Horowitz; Paul Komesaroff; Michael Jelinek; David L Hare
Journal:  Curr Cardiol Rev       Date:  2021

Review 4.  A Review of the External Validity of Clinical Trials with Beta-Blockers in Heart Failure.

Authors:  Pupalan Iyngkaran; Samia R Toukhsati; Merlin C Thomas; Michael V Jelinek; David L Hare; John D Horowitz
Journal:  Clin Med Insights Cardiol       Date:  2016-10-12

Review 5.  Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria.

Authors:  P Iyngkaran; M Thomas
Journal:  Clin Med Insights Cardiol       Date:  2015-08-05

Review 6.  Chronic Heart Failure and Comorbid Renal Dysfunction - A Focus on Type 2 Cardiorenal Syndrome.

Authors:  Jois Preeti; Mebazaa Alexandre; Iyngkaran Pupalan; Thomas C Merlin; Ronco Claudio
Journal:  Curr Cardiol Rev       Date:  2016

Review 7.  Heart Failure in Minority Populations - Impediments to Optimal Treatment in Australian Aborigines.

Authors:  Pupalan Iyngkaran; Nadarajan Kangaharan; Hendrik Zimmet; Margaret Arstall; Rob Minson; Merlin C Thomas; Peter Bergin; John Atherton; Peter MacDonald; David L Hare; John D Horowitz; Marcus Ilton
Journal:  Curr Cardiol Rev       Date:  2016

Review 8.  Phase 4 Studies in Heart Failure - What is Done and What is Needed?

Authors:  Pupalan Iyngkaran; Danny Liew; Peter McDonald; Merlin C Thomas; Christopher Reid; Derek Chew; David L Hare
Journal:  Curr Cardiol Rev       Date:  2016
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.